

*In a trial that evaluated Opdualag, toxicity was graded per NCI CTCAE V5.0.1
NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.
Infusion-Related Reactions
Opdualag can cause severe infusion-related reactions. Discontinue Opdualag in patients with severe or life-threatening infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild to moderate infusion-related reactions. In patients who received Opdualag as a 60-minute intravenous infusion, infusion-related reactions occurred in 7% (23/355) of patients.
Learn more about the dosing schedule for this fixed-dose combination therapy.
A convenient, printable tool to help nurses identify signs and symptoms of immune-mediated adverse reactions.
Reference: